Abstract
Treatment access programmes are currently expanding in resource-limited settings. The potential barriers to long-term success (such as intermittent drug supply drug stock-outs poor patient monitoring incorrect prescribing practices and low adherence) as well as the need to begin programmes quickly to treat millions of individuals have raised fears that the aggressive plan to roll out antiretroviral therapy (ART) particularly in Africa may generate an epidemic of drug-resistant strains of HIV. (excerpt)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
